Nivolumab in refractory cerebral relapse of Hodgkin’s lymphoma
| العنوان: | Nivolumab in refractory cerebral relapse of Hodgkin’s lymphoma |
|---|---|
| المؤلفون: | Cécile Borel, Sarah Péricart, Camille Laurent, Lucie Oberic, Leopoldine Lapierre, Loic Ysebaert, Caroline Protin |
| المصدر: | Leukemia & Lymphoma. 62:3063-3065 |
| بيانات النشر: | Informa UK Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Brentuximab Vedotin, Oncology, Cancer Research, medicine.medical_specialty, Immunoconjugates, business.industry, Hematology, Favorable prognosis, Hodgkin's lymphoma, medicine.disease, Hodgkin Disease, Lymphoma, Regimen, Nivolumab, Refractory, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Hematological neoplasm, Neoplasm Recurrence, Local, business |
| الوصف: | Hodgkin’s lymphoma (HL) is a hematological neoplasm generally related to a favorable prognosis, since approximately 80% of patients will be cured with actual regimen treatment. However, 10 to 30% o... |
| تدمد: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2021.1950711 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742119fb0ae0550489075866465c6393 https://doi.org/10.1080/10428194.2021.1950711 |
| رقم الانضمام: | edsair.doi.dedup.....742119fb0ae0550489075866465c6393 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10292403 10428194 |
|---|---|
| DOI: | 10.1080/10428194.2021.1950711 |